Archives
-
IBDV VP3 Disrupts IRF7 Antiviral Signaling
2026-10-07
A 2025 study links the IBDV VP3 protein to suppression and proteasome-associated degradation of chicken IRF7, a key regulator of type I interferon responses. The findings provide a mechanistic framework for viral immune evasion while remaining primarily cell-based and requiring validation in broader infection models.
-
Bergeyella cardium and Floatptosis in Macrophages
2026-10-07
A 2025 Cell Discovery study identifies floatptosis, a lysosome-fusion-associated form of cytoplasmic vacuolization cell death triggered by a Bergeyella cardium variant in macrophages. The work connects this phenotype to outer membrane vesicles, barrel-like proteins, amiloride-sensitive signaling, and SLC9A9-dependent vacuole fusion while defining important boundaries for interpreting related autophagy and PI3K studies.
-
From Lysate Integrity to Translational Signal
2026-10-06
A mechanistic and translational perspective on how protease control can strengthen interpretation of liver-injury and phospho-signaling studies, using recent lanthanum hepatotoxicity research as a case study.
-
Phosphatase Inhibitor Cocktail 2: Five Key Questions
2026-10-06
A source-grounded overview of how phosphatase inhibition supports protein phosphorylation preservation, what the Nguyen et al. mouse study does and does not show, and where product claims require cautious interpretation.
-
LY294002 in PI3K/Akt Signaling Research
2026-10-05
This source-grounded overview examines LY294002, also known as 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, as a research probe for PI3K/Akt/mTOR signaling. It places the compound in the context of a 2024 study of colitis-associated colorectal cancer, where LY294002 was one pharmacological antagonist used to interrogate signaling linked to macrophage polarization. The evidence supports a hypothesis-generating role for PI3K-related signaling but does not establish LY294002 as a selective therapeutic or prove that PI3K inhibition alone caused the reported effects.
-
Dibutyryl-cAMP in Pain Signaling Research
2026-10-05
A source-grounded overview of Dibutyryl-cAMP, sodium salt as a research tool, with emphasis on cAMP signaling, trigeminal pain mechanisms, evidence strength, conceptual applications, and limitations of current animal and in vitro findings.
-
Hexose Diphosphate: Evidence and Research Context
2026-10-04
A source-grounded overview of hexose diphosphate, its place in carbohydrate metabolism and energy homeostasis research, and why recent phosphoenolpyruvate findings should not be treated as direct evidence for this distinct metabolite.
-
PP 1 in Src Kinase Research: Evidence and Limits
2026-10-03
PP 1 is a research small molecule described as an inhibitor of Src-family kinases, including Lck and Fyn. This overview separates supplier-reported pharmacology from peer-reviewed findings on EDI3 in therapy-resistant breast cancer, highlighting conceptual applications, evidence strength, and important limits on interpretation.
-
OSMI-1 for O-GlcNAc Transferase Studies
2026-10-02
Use OSMI-1 as a cell-permeable O-GlcNAc transferase inhibitor to test how reduced protein O-GlcNAc modification influences trophoblast stress, ferroptosis, and syncytialization. This guide translates the HUWE1–TfR1 findings into dose-controlled workflows, orthogonal readouts, and practical troubleshooting.
-
SIS3 (Smad3 Inhibitor) in Fibrosis Research
2026-10-01
SIS3 is a selective Smad3 inhibitor that is used to interrogate TGF-β signaling in fibrosis, renal fibrosis models, diabetic nephropathy research, and osteoarthritis studies. Product information describes Smad3 phosphorylation selectivity, while peer-reviewed rat osteoarthritis data show reduced ADAMTS-5 expression after SIS3 exposure.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-10-01
The reference study develops a non-viral, localized tumor suppressor replacement strategy in which chemically modified CDKN1A/p21 mRNA is encapsulated in lipid nanoparticles and delivered intravesically. Its findings connect bladder-localized p21 restoration with cell-cycle inhibition, DNA-damage signaling, apoptosis, and reduced tumor growth in an orthotopic mouse model.
-
Amiloride (MK-870): From Ion Flux to Entry Biology
2026-09-30
Amiloride (MK-870) is most informative when used as a mechanistic probe rather than a generic pathway blocker. This article connects ENaC and PC2-related ion transport with a carefully bounded interpretation of endocytosis data, showing how negative results can sharpen translational research strategy.
-
Phosbind Acrylamide for Phosphorylation Workflows
2026-09-30
Phosbind Acrylamide enables antibody-independent comparison of phosphorylated and non-phosphorylated proteins through phosphate-affinity SDS-PAGE. This guide translates a published HBV capsid workflow into practical setup, optimization, and troubleshooting strategies for signaling, kinase, and comparative phosphorylation studies.
-
Pomegranate Peel Polyphenols in Acne Inflammation
2026-09-29
Wang et al. investigated how pomegranate peel polyphenols affect acne-related inflammation using Cutibacterium acnes-treated rats and LPS-stimulated RAW264.7 macrophages. The findings connect reduced inflammatory mediator production with suppression of the Notch/NF-κB pathway, while also highlighting the need for better causal and translational validation.
-
Gallein and the Next Frontier of GPCR Translation
2026-09-29
Gallein, a G protein βγ subunit inhibitor, offers a pathway-level strategy for testing how GPCR signaling connects metabolic control with cancer, immunology, and cardiac disease. This thought-leadership analysis places Gallein alongside the lactate–GPR81/FARP1 axis and outlines practical, translationally oriented workflows.